Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,723,000 | 6,933,000 | 7,071,000 | 4,495,000 | 3,687,000 |
| Depreciation Amortization | 3,243,000 | 3,267,000 | 3,538,000 | 3,327,000 | 3,014,000 |
| Accounts receivable | -356,000 | -68,000 | -383,000 | -924,000 | -275,000 |
| Other Working Capital | -2,475,000 | -1,519,000 | -771,000 | -892,000 | -1,331,000 |
| Other Operating Activity | 1,126,000 | 968,000 | 1,078,000 | 1,895,000 | 1,041,000 |
| Operating Cash Flow | $7,261,000 | $9,581,000 | $10,533,000 | $7,901,000 | $6,136,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,202,000 | -1,777,000 | -1,885,000 | -2,177,000 | -1,638,000 |
| Net Acquisitions | -837,000 | 48,000 | -53,000 | 16,000 | -122,000 |
| Purchase Of Investment | -159,000 | -185,000 | -173,000 | -83,000 | -103,000 |
| Sale Of Investment | 43,000 | 152,000 | 77,000 | 10,000 | 21,000 |
| Other Investing Activity | 22,000 | 22,000 | 26,000 | 19,000 | 27,000 |
| Investing Cash Flow | $-3,133,000 | $-1,740,000 | $-2,008,000 | $-2,215,000 | $-1,815,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 21,000 | 47,000 | -204,000 | 2,000 | N/A |
| Debt Issued | 2,000 | 7,000 | 4,000 | 1,281,000 | 1,842,000 |
| Debt Repayment | -2,498,000 | -753,000 | -48,000 | -1,333,000 | -3,441,000 |
| Common Stock Issued | 167,000 | 167,000 | 255,000 | 245,000 | 298,000 |
| Common Stock Repurchased | -1,227,000 | -3,795,000 | -2,299,000 | -403,000 | -718,000 |
| Dividend Paid | -3,556,000 | -3,309,000 | -3,202,000 | -2,560,000 | -2,270,000 |
| Other Financing Activity | 0 | 0 | 0 | -11,000 | 0 |
| Financing Cash Flow | $-7,091,000 | $-7,636,000 | $-5,494,000 | $-2,779,000 | $-4,289,000 |
| Exchange Rate Effect | -23,000 | -122,000 | -70,000 | 71,000 | -16,000 |
| Beginning Cash Position | 9,882,000 | 9,799,000 | 6,838,000 | 3,860,000 | 3,844,000 |
| End Cash Position | 6,896,000 | 9,882,000 | 9,799,000 | 6,838,000 | 3,860,000 |
| Net Cash Flow | $-2,986,000 | $83,000 | $2,961,000 | $2,978,000 | $16,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,261,000 | 9,581,000 | 10,533,000 | 7,901,000 | 6,136,000 |
| Capital Expenditure | -2,202,000 | -1,777,000 | -1,885,000 | -2,177,000 | -1,638,000 |
| Free Cash Flow | 5,059,000 | 7,804,000 | 8,648,000 | 5,724,000 | 4,498,000 |